Exciting New Treatment Approaches for Pathyphysiologic Mechanisms of Sickle Cell Disease

References

• Charache S, Terrin M L, Moore R D, et al. Effects of hydroxyurea on the frequency of painful crises in sickle cell anemia. N Engl J Med 1995; 332: 1017–1022
   Google Scholar
• Ley T J, DeSimone J, Noguchi C T, et al. 5–Azacytidine increases gamma globin synthesis and reduces the proportion of dense cells in patients with sickle cell anemia. Blood 1983; 62: 370–380
   PubMed Web of Science ®Google Scholar
• Platt O S, Orkin S H, Dover G, et al. Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia. J Clin Invest 1984; 74: 652–656
   PubMed Web of Science ®Google Scholar
• Veith R, Galanello R, Papayannopoulou T, Stamatoyannopoulos G. Stimulation of F-cell production in patients with sickle cell anemia treated with cytarabine or hydroxyurea. N Engl J Med 1985; 313: 1571–1575
   PubMed Web of Science ®Google Scholar
• Krakoff I H, Brown N C, Reichard P. Inhibition of ribonucleoside diphosphate reductase by hydroxyurea. Cancer Res 1968; 28: 1559–1565
   PubMed Web of Science ®Google Scholar
• Mankad V N, Baliga S, Phillips K, et al. Relationship of burst forming unit erythroid progenitors and their DNA synthesis stage to fetal hemoglobin levels in dydroxyurea treated patients with sickle cell anemia. Am J Hematol 1994; 46: 259–263
   Google Scholar
• Ballas S K, Dover G J, Charache S. The effect of hydroxyurea on the rheological properties of sickle erythrocytes in vivo. Am J Hematol 1989; 32: 104
   PubMed Web of Science ®Google Scholar
• Orringer E P, Blythe D S, Johnson A E, et al. Effects of hydroxyurea on hemoglobin F and water content in the red blood cells of dogs and of patients with sickle cell anemia. Blood 1991; 78: 212–216
   PubMedGoogle Scholar
• Bridges K R, Barabino G D, Brugnara C, et al. A multiparameter analysis of sickle erythrocytes in patients undergoing hydroxyurea therapy. Blood 1996; 88(12)4701–4710
   PubMed Web of Science ®Google Scholar
• Miller S T, Sleeper L A, Pagelow C H, et al. Prediction of adverse outcomes in children with sickle cell disease. N Engl J Med 2000; 342: 83–89
   PubMed Web of Science ®Google Scholar
• Adrangna N C, Fonseca P, Lauf P K. Hydroxyurea affects cell morphology, cation transport, and red blood cell adhesion in cultured vascular endothelial cells. Blood 1994; 83: 553–560
   Google Scholar
• Scott J P, Hillery C A, Brown E R, et al. Hydroxyurea therapy in children severely affected with sickle cell disease. J Pediatr 1996; 128: 820–828
   PubMed Web of Science ®Google Scholar
• Ferster A, Vermylen C, Cornu G, et al. Hydroxyurea for treatment of severe sickle cell anemia: a pediatric clinical trial. Blood 1996; 88: 1960–1964
   PubMed Web of Science ®Google Scholar
• Jayabose S, Tugal O, Sandoval C., et al. Clinical and hematological effects of hydroxyurea in children with sickle cell anemia. J Pediatr 1996; 129: 559–565
   PubMed Web of Science ®Google Scholar
• Olivieri N F, Vichinsky E P. Hydroxyurea in children with sickle cell disease: impact on splenic function and compliance with therapy. J Pediatr Hematol Oncol 1998; 20: 26–31
   PubMed Web of Science ®Google Scholar
• Kinney T R, Helms R W, O'Branski E E, et al. Safety of hydroxyurea in children with sickle cell anemia: Results of the HUG-KIDS study, a phase I/II trial. Blood 1999; 94: 1550–1554
   PubMed Web of Science ®Google Scholar
• Wang W W, Wynn L, Rogers Z, et al. Effects of hydroxyurea in very young children with sickle cell disease: a pilot trial. 23rd Annual Meeting of the National Sickle Cell Program, San Francisco, March 6–9, 1999, 167
   Google Scholar
• Horiuchi K, Golden J A, Das S K, et al. Adverse effects of hydroxyurea on growth and development of young mice. Blood 1998; 92: 160a
   PubMedGoogle Scholar
• Weinfeld A, Swolin B, Westin J. Acute leukemia after hydroxyurea therapy in polycythemia and allied disorders: Prospective study of efficacy and leukemogenicity with therapeutic implications. Eur J Haematol 1994; 52: 134–139
   PubMed Web of Science ®Google Scholar
• Berk P D, Wasserman L R, Fruchtman S M, Goldberg J D. Treatment of polycythemia vera: a summary of the clinical trials conducted by the Polycythemia Vera Study Group. Polycythemia Vera and Myeloproliferative Disorders, L R Wasserman, P D Berk, N I Berlin. WB Saunders, Philadelphia 1995; 166–194
   Google Scholar
• Triadou P, Maier-Redelsperger M, Krishnamoorty R, et al. Fetal haemoglobin variations following hydroxyurea treatment in patients with cyanotic congenital heart disease. Nouv Rev Fr Hematol 1994; 36: 367–372
   PubMedGoogle Scholar
• Mougiou A, Kouka M, Mavroyanni D, et al. Cytogenetic and molecular (p53 and ras) studies in sickle cell patients receiving hydroxyurea over long periods do not indicate an increased risk for leukemia. Blood 1997; 90(suppl)2818
   Google Scholar
• Hanft V N, Fruchtman S R, Pickens C V, et al. Acquired DNA mutations associated with in vivo hydroxyurea exposure. Blood 2000; 95: 3589–3593
   PubMed Web of Science ®Google Scholar
• Claster E, Vichinsky E. First report of reversal of organ dysfunction in sickle cell anemia by the use of hydroxyurea: splenic regeneration. Blood 1996; 88: 1951–1953
   PubMed Web of Science ®Google Scholar
• Wang W, Day S, Wynn L, et al. Lack of improvement in organ function in older children with sickle cell anemia treated with hydroxyurea. Blood 1998; 92(Suppl)2830
   Google Scholar
• Ware R E, Steinberg M H, Kinney T R. Hydroxyurea: an alternative to transfusion therapy for stroke in sickle cell anemia. Am J Hematol 1995; 50(2)140–143
   Google Scholar
• Vichinsky E P, Lubin B. A cautionary note regarding hydroxyurea in sickle cell disease. Blood 1994; 83: 1124–1128
   PubMed Web of Science ®Google Scholar
• Ware R E, Zimmerman S A, O'Branski E E, et al. Hydroxyurea as an alternative to blood transfusions for the prevention of recurrent stroke in children with sickle cell disease. 23rd Annual Meeting of the National Sickle Cell Disease Program, San Francisco, March 6–9, 1999, 172
   Google Scholar
• Adams R J, McKie V C, Hsu L, et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N Engl J Med 1998; 339: 5–11
   PubMed Web of Science ®Google Scholar
• Perrine S, Ginder G D, Faller D V, et al. A short term trial of butyrate to stimulate fetal globin gene expression in the beta globin disorders. New Engl J Med 1993; 328: 81–86
   PubMed Web of Science ®Google Scholar
• Atweh G F, Sutton M, Nassif I, et al. Sustained induction of fetal hemoglobin by pulse butyrate therapy in sickle cell disease. Blood March 15, 1999; 93(6)1790–1797
   PubMed Web of Science ®Google Scholar
• Torkelson S, White G L, Phipps K, et al. Erythroid progenitor proliferation is stimulated by phenoxyacetic and phenylalkyl acids. Blood Cells Mol Dis 1996; 20: 150–158
   Google Scholar
• Dover G J, Brusilow S, Charache S. Induction of fetal hemoglobin production in subjects with sickle cell anemia by oral sodium phenylbutyrate. Blood 1994; 84(1)339–343
   Google Scholar
• Boosalis M S, Ikuta T, Pace B S, et al. Abrogation of IL-3 requirements and stimulation of hematopoietic cell proliferation in vitro and in vivo by carboxylic acids. Blood Cells Mol Dis 1997; 23: 434–442
   Google Scholar
• Brugnara C, Gee B, Armsby C C, et al. Therapy with oral clotrimazole induces inhibition of the Gardos Channel and reduction of erythrocyte dehydration in patients with sickle cell disease. J Clin Invest 1996; 97: 1227–1234
   PubMed Web of Science ®Google Scholar
• Brugnara C, Tosteson D C. Inhibition of K transport by divalent cations in sickle erythrocytes. Blood 1987; 70: 1810–1815
   PubMed Web of Science ®Google Scholar
• De Franceschi L, Bachir D, Galacteros F, et al. Oral magnesium supplements reduce erythrocyte dehydration in patients with sickle cell disease. J Clin Invest 1997; 100: 1847–1852
   PubMed Web of Science ®Google Scholar
• Adams-Graves P, Kedar A, Koshy M, et al. RheothRx (poloxamer 188) injection for the acute painful episode of sickle cell disease; a pilot study. Blood Sept 1, 1997; 90(5)2041–2046
   PubMed Web of Science ®Google Scholar
• Kaul D K, Tsai X D, Liu D, et al. Monoclonal antibodies to αVβ3 (7E3 and LM609) inhibit sickle red blood cell-endothelium interactions induced by platelet activating factor. Blood Jan 15, 2000; 95: 368–374
   PubMed Web of Science ®Google Scholar
• Harlan J M. Introduction: anti-adhesion therapy in sickle cell disease. Blood Jan 15, 2000; 365–367
   Google Scholar
• Salvaggio J E, Arnold C A, Banov C H. Long term anticoagulation in sickle cell disease. N Engl J Med 1963; 269: 182–186
   PubMed Web of Science ®Google Scholar
• Wolters H J, ten Cate H, Thomas L L, et al. Low intensity oral anticoagulation in sickle cell disease. Br J Haematol 1995; 90: 715–717
   Google Scholar
• Head C A, Brugnara C, Martinez-Ruiz R, et al. Low concentration of nitric oxide increases oxygen affinity of sickle erythrocytes in vitro and in vivo. J Clin Invest 1997; 100: 1193–1198
   PubMed Web of Science ®Google Scholar
• Gladwin M T, Schecter A N, Shelhamer J H, et al. Inhaled nitric oxide augments nitric oxide transport on sickle cell hemoglobin without affecting oxygen affinity. J Clin Invest 1999; 104: 937–945
   PubMed Web of Science ®Google Scholar
• Hammerman S I, Klings E S, Hendra K P. Endothelial cell nitric oxide production in acute chest syndrome. Am J Physiol Oct, 1999; 277(4 Pt 2)1579–1592
   Google Scholar
• Nagel R L. Can we just say NO to sickle cell anemia. J Clin Invest 1999; 104: 847–848
   Google Scholar
• Giardini C, Lucarelli G. Bone marrow transplantation for beta-thalassemia. Hematol Oncol Clin North Am Oct, 1999; 13(5)1059–1064
   PubMed Web of Science ®Google Scholar
• Walters M C, Storb R, Patience M, et al. Impact of bone marrow transplantation for symptomatic sickle cell disease, an interim report. Blood 2000; 95: 1918–1924
   PubMed Web of Science ®Google Scholar
• Blouin M, Beauchemin H, Wright A, et al. Genetic correction of sickle cell disease: insights using transgenic mouse models. Nature Med Feb, 2000; 6(2)177–182
   PubMed Web of Science ®Google Scholar
• Karlsson S. The first step on the gene therapy pathway to anti-sickling success. Nature Med Feb, 2000; 6(2)139–140
   Google Scholar